ADC Therapeutics SA
ADCT
$1.89
$0.2011.83%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.03M | 16.91M | 18.46M | 17.41M | 18.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.03M | 16.91M | 18.46M | 17.41M | 18.05M |
| Cost of Revenue | 2.06M | 110.16M | 1.84M | 25.51M | 2.51M |
| Gross Profit | 20.97M | -93.25M | 16.62M | -8.10M | 15.54M |
| SG&A Expenses | 20.51M | 20.87M | 20.68M | 20.94M | 23.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.50M | 49.35M | 54.03M | 46.45M | 51.67M |
| Operating Income | -28.46M | -32.44M | -35.56M | -29.04M | -33.61M |
| Income Before Tax | -38.44M | -31.05M | -43.88M | -36.31M | -46.44M |
| Income Tax Expenses | 165.00K | -321.00K | 90.00K | 234.00K | 163.00K |
| Earnings from Continuing Operations | -38.60M | -30.73M | -43.97M | -36.54M | -46.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.60M | -30.73M | -43.97M | -36.54M | -46.61M |
| EBIT | -28.46M | -32.44M | -35.56M | -29.04M | -33.61M |
| EBITDA | -28.12M | -32.10M | -35.23M | -28.72M | -33.28M |
| EPS Basic | -0.36 | -0.29 | -0.42 | -0.38 | -0.56 |
| Normalized Basic EPS | -0.22 | -0.18 | -0.26 | -0.24 | -0.35 |
| EPS Diluted | -0.36 | -0.29 | -0.42 | -0.38 | -0.56 |
| Normalized Diluted EPS | -0.22 | -0.18 | -0.26 | -0.24 | -0.35 |
| Average Basic Shares Outstanding | 107.20M | 105.40M | 104.82M | 95.69M | 82.55M |
| Average Diluted Shares Outstanding | 107.20M | 105.40M | 104.82M | 95.69M | 82.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |